Is axillary dissection further required in clinically node negative breast cancer?;Ist die axilladissektion beim klinisch nodal negativen mammakarzinom welter indiziert?

Strahlentherapie und Onkologie

Volumn 174, Issue 12, 1998, Pages 605-612

  Böhler, Franz K ^a,b   Eiter, Helmut ^a   Rhomberg, Walter ^a  

^a Landeskrankenhaus Feldkirch   (Austria)

^b GENERAL HOSPITAL KLAGENFURT   (Austria)

Author keywords

Axillary dissection; Breast cancer; Definitive axillary radiotherapy; Sentinel node dissection

Indexed keywords

BREAST CANCER; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; METASTASIS; REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0031797771     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03038507     Document Type: Review

References (125)

1. Albain K, Green S, Osborne K, et al. Tamoxifen (T) versus cyclophosphamide, adriamycin and 5-FU plus either concurrent or sequential T in postmenopausal, receptor (+), node (+) breast cancer: A Southwest Oncology Group phase III intergroup trial (SWOG-8814, INT-0100). Proc Am Soc Clin Oncol 1997;16:128a.abstract.
2. Albertini J, Cox C, Yeatman T, et al. Lymphatic mapping and sentinel node biopsy in the breast cancer patient. Proc Am Soc Clin Oncol 1995;14:A99.abstract.
3. Albertini JJ, Lyman GH, Cox C, et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 1996;276:1818-22.
4. Amalric R, Santamaria F, Robert F, et al. Radiationtherapy with or without primary limited surgery for operable breast cancer A 20-year experience at the Marseilles Cancer Institute. Cancer 1982;49:30-4.
5. Ashikari R, Huvos AG, Snyder RE. Prospective study of non-infiltrating carcinoma of the breast. Cancer 1977;39:435-9.
6. Atkins H, Hayward JL, Klugman DJ, et al. Treatment of early breast cancer: A report after 10 years of a clinical trial. Br Med J 1972;5:423-9.
7. Axelsson CK, Mouridsen HT, Zedeler K. Axillarydissection of level I and II lymph nodes is important in breast cancer classification. The Danish Breast Cancer Cooperative Group (DBCG). Eur J Cancer 1993;28: 1415-8.
8. Baeza MR, Sole J, Leon A, et al. Conservative treatment of early breast cancer. Int J Radiat Oncol Biol Phys 1988;14:669-76.
9. Bailey L, Scanlon EF, Reid SE, Bernstein JR, Paige M, Matsumura J. Occult breast cancer: a small number behave aggressively. Breast Cancer Res Treat 1990;16:183.abstract.
10. Baker LH. Breast Cancer Detection Demonstration Project. Five-year summary report. CA Cancer J Clin 1982;32:194-225.
11. Beitsch PD, Kirgan DM, Guenther JM, et al. Improved microstaging of axillary lymph nodes in breast cancer. Breast Cancer Res Treat 1994;32: Suppl:94.abstract.
12. Böhler FK, Rhomberg W, Doringer W. Hypertonie als Risikofaktor für erhöhte Nebenwirkungsraten im Rahmen der Mammakarzinombestrahlung. Strahlenther Onkol 1992;168:344-9.
13. Brinkley D, Haybittle JL. Treatment of stage II carcinoma of the female breast. Lancet 1966;2:291-5.
14. Brinkley D, Haybittle JL. Treatment of stage II carcinoma of the female breast (letter). Lancet 1971;2:1086-7.
15. Britton RC, Nelson PA. Causes and treatment of postmastectomy lymphedema of the arm: Report of 114 cases. JAMA 1962;180:95.
16. Brice J. Operable cancer of the breast: A controlled clinical trial. Cancer 1971;28:1443-52.
17. Cabanes PA, Salmon RJ, Vilcoq JR, et al. Value of axillary dissection in addition to lumpectomy and radiotherapy in early breast cancer. Lancet 1992;339:1245-8.
18. Cady B, Stone M, Wayne J. New therapeutic possibilities in primary invasive breast cancer. Ann Surg 1993;218:338-49.
19. Cady B. The need to reexamine axillary lymph node dissection in invasive breast cancer. Cancer 1994;73:505-8.
20. Cady B. Is axillary lymph node dissection necessary in routine management of breast cancer? No. Import Adv Oncol 1996:251-65.
21. Calle R, Vilcoq JR, Zafrani B, et al. Local control and survival of breast cancer treated by limited surgery followed by irradiation. Int J Radiat Oncol Biol Phys 1986;12:873-8.
22. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989;63:181-7.
23. Cerrotta A, Lozza L, Kenda R, et al. Current controversies in the therapeutic approach to early breast cancer in the elderly. Rays 1991;11:Suppl 1:66-8.
24. Chen KT, Chang KJ, Chan YZ, et al. Factors affecting local or regional recurrence in breast cancer. J Formosan Med Assoc 1991;90:986-92.
25. Ciatto S, Del Turco R, Bonardi R, et al. Non-palpable lesions of the breast detected by mammography-review of 1182 consecutive histologically confirmed cases. Eur J Cancer 1994;30A:40-4.
26. Crile G. Results of simplified treatment of breast cancer. Surg Gynecol Obstet 1964;118:517-23.
27. Crump M, Prince M, Gross P. Outcome of extensive evaluation of women with > 10 positive axillary lymph nodes prior to adjuvant therapy for breast cancer. Proc Am Soc Clin Oncol 1995;14:107a.abstract.
28. Debois JM. The significance of a supraclavicular node metastasis in patients with breast cancer. A literature review. Strahlenther Onkol 1997;173:1-12.
29. De Graaf H, Willemse PHB, DeVries EGE, et al. Intensive Chemotherapy with autologous bone marrow transfusion as primary treatment in women with breast cancer and more than five involved axillary lymph nodes. Eur J Cancer 1994;30A:150-4.abstract.
30. Delouche G, Bachelot F, Premont M, et al. Conservation treatment of early breast cancer: Long term results and complications. Int J Radiat Oncol Biol Phys 1987;13:29-34.
31. Early Breast Cancer Trialists Collaborative Group. Effects of adjuvant tamoxifen and cytotoxic therapy on mortality in early breast cancer. N Engl J Med 1988;319:1681-2.
32. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992;339:1-15.
33. Early Breast Cancer Trialists' Collaborative Group. Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. N Engl J Med 1995;333:1444-55.
34. Fein DA, Fowble BL, Hanlon AI, et al. Identification of women with T1-2 breast cancer at low risk of positive axillary nodes. J Surg Oncol 1997;65: 34-9.
35. Fisher B, Slack NH, Ausman RK. Location of breast carcinoma and prognosis. Surg Gynecol Obstet 1969;129:705-16.
36. Fisher B, Slack N, Katrych D, et al. Ten-year follow up results of patients with carcinoma of toe breast in a cooperative clinical trial evaluating surgical adjuvant chemotherapy. Surg Gynecol Obstet 1975;140:528-34.
37. Fisher B, Redmond C, Fisher ER, et al. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 1985;312:674-81.
38. Fisher B, Redmond C, Dimitrov NV, et al. A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. N Engl J Med 1989;320:473-8.
39. Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989;320:479-84.
40. Fisher B, Anderson S, Redmond CK, et al. Reanalysis and results after 12 years of follow-up in a randomised clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 1995;333:1458-61.
41. Fisher B, Dignam J, DeCillis A, et al. The worth of chemotherapy and tamoxifen (TAM) over TAM alone in node-negative patients with estrogen-receptor positive invasive breast cancer. The first results from NS-ABP-20. Proc Am Soc Clin Oncol 1997;16:1a.abstract.
42. Forrest APM, Stewart HJ, Roberts MM, et al. Simple mastectomy and axillary node sampling (pectoral node biopsy) in the management of primary breast cancer. Ann Surg 1982;196:371-8.
43. Fowble B, Solin U, Schultz DJ, et al. Frequences, sites of relapse, and outcome of regional node failures following conservative surgery and radiation for early breast cancer. Int J Radiat Oncol Biol Phys 1989;17:703-10.
44. Fowble B, Schultz DJ, Overmoyer B, et al. The influence of young age on outcome in early stage breast cancer. Int J Radiat Oncol Biol Phys 1994;30:23-33.
45. Gately CA, Mansel RE, Owen A, et al. Treatment of the axilla in operable breast cancer. Br J Surg 1991;78:750.abstract.
46. Gianni AM, Siena S, Bregni M, et al. Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary lymph nodes: 5 year results. J Clin Oncol 1997;15:2312-21.
47. Giuliano AE, Kirgan DM, Guenther JM, et al. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994;220:391-9.
48. Giuliano AE, Barth AM, Spivack B, Beitsch PD, Evans SW. Incidence and predictors of axillary metastasis in T1 carcinoma of the breast. J Am Coll Surg 1996;183:185-9.
49. Giuliano AE, Jones RC, Brennan M, Statman R. Sentinel lymphadenectomy in breast cancer. J Clin Oncol 1997;15:2345-50.
50. Graveson HP, Blichert-Toft M, Andersen JA, et al. Breast cancer: risk of axillary recurrence in node-negative patients following partial dissection of the axilla. Eur J Surg Oncol 1988;14:407-12.
51. Haffty BG, Goldberg NB, Fisher D, et al. Conservative surgery and radiotherapy in breast carcinoma: Local recurrence and prognostic implications. Int J Radiat Oncol Biol Phys 1989;17:727-32.
52. Haffty BG, Fisher D, Fisher JJ. Regional nodal irradiation in the conservative treatment of breast cancer. Int J Radiat Oncol Biol Phys 1990; 19:859-65.
53. Haffty BG, McKhann C, Beinfield M, et al. Breast conservation therapy without axillary dissection. Arch Surg 1993;128:1315-9.
54. Haffty BG, Ward B, Pathare P, et al. Reappraisal of the role of axillary lymph node dissection in the conservative treatment of breast cancer. J Clin Oncol 1997;15:691-700.
55. Halverson KJ, Garcia DM, Taylor ME, et al. Regional nodal management and patterns of failure following conservative surgery and radiation therapy for stage I and II breast cancer. Int J Radiat Oncol Biol Phys 1993;26: 593-9.
56. Halverson KJ, Taylor ME, Perez CA, et al. Management of the axilla in patients with breast cancers one centimeter or smaller. Am J Clin Oncol 1994;17:461-6.
57. Harris JR, Botnik L, Bloomer WD, et al. Primary radiation therapy for early breast cancer: The experience at the Joint Center for Radiation Therapy. Int J Radiat Oncol Biol Phys 1991;7:1549-52.
58. Hayward JL. The Guy's trial of treatments of "early" breast cancer. World J Surg 1977;1:314-6.
59. Hayward JL. The Guy's Hospital trials on breast conservation. In: Harris JR, Hellman S, Silen W, eds. Conservative management of breast cancer. New York: Lippincott, 1983:77-90.
60. Hayward J, Caleffi M. The significance of local control in the primary treatment of breast cancer. Arch Surg 1987;122:1244-7.
61. Hladiuk M, Huchcroft S, Temple W, et al. Arm function after axillary dissection for breast cancer: A pilot study to provide parameter estimates. J Surg Oncol 1992;50:47-52.
62. International Breast Cancer Study Group. Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients. J Clin Oncol 1997;15:1385-94.
63. Kaae S, Johansen H. Simple mastectomy plus postoperative irradiation by the method of McWhirter for mammary carcinoma. Ann Surg 1980;170: 895-9.
64. Keramopoulos A, Tsionou C, Minaretzis D, et al. Arm morbidity following treatment of breast cancer with total axillary dissection: A multivariated approach. Oncology 1993;50:445-9.
65. Kyle J. Management of early cancer of the breast. Report on an international multicentre trial supported by the Cancer Research Campaigne. Br Med J 1976;1:1035-8.
66. Langlands AO, Prescott RJ, Hamilton T. A clinical trial in the management of operable cancer of the breast. Br J Surg 1980;67:170-4.
67. Larson D, Weinstein M, Goldberg I, et al. Edema of the arm as a function of the extent of axillary surgery in patients with stage I-II carcinoma of the breast treated with primary radiotherapy. Int J Radiat Oncol Biol Phys 1986;12:1575-82.
68. Leborgne F, Leborgne JH, Ortega B, et al. Breast conservation treatment of early stage breast cancer: Patterns of failure. Int J Radiat Oncol Biol Phys 1995;31:765-75.
69. Le Doussal V, Tubiana-Hulin M, Friedman S, et al. Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer 1989 64:1914-21.
70. Leung S, Otmezguine Y, Calitchi E, Mazeron JJ, Le Bourgeois JP, Pierquin B. Locoregional recurrences following radical external beam irradiation and interstitial implantation for operable breast cancer - a twenty-three year experience. Radiother Oncol 1986;5:1-10.
71. Lin PP, Allison DC, Wainstock J, et al. Impact of axillary node dissection on the therapy of breast cancer patients. J Clin Oncol 1993;11:1536-44.
72. Lythgoe JP. Manchester regional breast study: Preliminary results. Lancet 1978;1:744-7.
73. Lythgoe JP, Palmer MK. Manchester regional breast study: Five- and ten-year results. Br. J Surg 1982;69:693-6.
74. Mansour EG, Gray R, Shatila AH, et al. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer: An intergroup study. N Engl J Med 1989;320:485-90.
75. Maunsell E, Brisson J, Deshenes L. Arm problems and psychological distress after surgery for breast cancer. Can J Surg 1993;36:315-20.
76. Mazeron JJ, Otmezguine Y, Huart J, et al. Conservative treatment of breast cancer: Results of management of axillary lymph node area in 3353 patients (letter). Lancet 1985;1:1387.
77. McDivitt RW, Boyce W, Gersell D. Tubular carcinoma of the breast. Clinical and pathological observations concerning 135 cases. Am J Surg Pathol 1982;6:401-11.
78. Meijer S, Collet GH, Pijpers HJ, et al. Less axillary dissection necessary due to sentinel node biopsy in patients with breast carcinoma. Ned Tijdschr Geneesk 1996;140:2239-43.
79. Morrow M. Axillary dissection: When and how radical? Semin Surg Oncol 1996;12:321-7.
80. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392-9.
81. Mustafa IA, Cole B, Wanebo HG, et al. The impact of histopathology on nodal metastases in minimal breast cancer. Arch Surg 1997;132:384-91.
82. Nemoto T, Vana J, Bedwani RN, et al. Management and survival of female breast cancer: Results of a national survey by the American College of Surgeons. Cancer 1980;45:2917-24.
83. Nevin JE, Pinzon G, Moran Th, et al. minimal breast cancer. Am J Surg 1980;139:357-9.
84. NIH Consensus Development Panel. Treatment of early stage breast cancer. J Natl Cancer Inst 1992;11:1-5.
85. Peters GN, Wolff M, Haagensen CD. Tubular carcinoma of the breast. Clinical pathologic correlations based on 100 cases. Ann Surg 1981;193: 139-49.
86. Peters WP, Ross M, Vredenburgh JJ, et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993;11:1132-43.
87. Pierce SM, Recht A, Lingos TI, et al. Long-term radiation complications following conservative surgery and radiation therapy in patients with early state breast disease. Int J Radiat Oncol Biol Phys 1992;23:915-23.
88. Pierquin B, Owen R, Maylin C, et al. Radical radiation therapy of breast cancer. Int J Radiat Oncol Biol Phys 1980;6:17-24.
89. Pierquin B, Mazeron JJ, Glaubiger D. Conservative treatment of breast cancer in Europe: report of the Groupe Europeen de Curietherapie. Radiother Oncol 1986;6:187-8.
90. Ptaszynski A, Van der Bogaert W, Van Glabbeke M, et al. Patient population analysis in EORTC Trial 22881/10882 on the role of a booster dose in breast-conserving therapy. Eur J Cancer 1994;30A:2073-81.
91. Rahman Z, Frye D, Buzdar A, et al. Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy. J Clin Oncol 1997;15:3171-7.
92. Ravdin PM, De Laurentiis M, Vendely T, et al. Prediction of axillary lymph node status in breast cancer patients by use of prognostic indicators. J Natl Cancer Inst 1994;86:1771-5.
93. Recht A, Pierce SM, Abner A, et al. Regional nodal failure after conservative surgery and radiotherapy for early-stage breast carcinoma. J Clin Oncol 1991;9:988-96.
94. Recht A, Houlihan MJ. Axillary lymph nodes and breast cancer: A review. Cancer 1995;76:1491-512.
95. Ribeiro GG, Magee B, Swindell R, et al. The Christie Hospital breast conservation trial: an update at 8 years from inception. Clin Oncol 1993;5:278-83.
96. Rosner D, Bedwani RN, Vana J, et al. Noninvasive breast carcinoma. Results of a national survey by the American College of Surgeons. Ann Surg 1980;192:139-47.
97. Rosen PP, Groshen S, Kinne DW, et al. Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up. J Clin Oncol 1993;11:2090-100.
98. Rutquist LE, Cedermark B, Glas U, et al. Randomized trial of adjuvant tamoxifen combined with post-operative radiotherapy or adjuvant chemotherapy in postmenopausal breast cancer. Cancer 1990;66:89-96.
99. Sarrazin D, Dewar JA, Arriagada R, et al. Conservative management of breast cancer. Br J Surg 1986;73:604-6.
100. Sauer R. Einfluß der lokalen Kontrolle auf das Gesamtüberleben nach brusterhaltender Therapie des Mammakarzinoms. Strahlenther Onkol 1996;172:181-5.
101. Schnabel FR, Estabrook A. Results of axillary lymph node dissection in early breast cancer. Breast Cancer Res Treat 1994;32:Suppl:40.abstract.
102. Schwartz GF, Feig SA, Rosenberg AL, et al. Staging and treatment of clinically occult breast cancer. Cancer 1984;53:1379-84.
103. Seidman JD, Schnapper LA, Aisner SC. Relationship of the size of the invasive component of the primary breast carcinoma to axillary lymph node metastases. Cancer 1995;75:65-71.
104. Silverstein MH, Waisman JR, Gamagami P, et al. Intraductal carcinoma of the breast (208 cases). Clinical factors influencing treatment choice. Cancer 1990;66:102-8.
105. Silverstein MJ, Gierson ED, Waisman JR, et al. Axillary lymph node dissection for T1a breast carcinomas: is it indicated? Cancer 1994;73: 664-7.
106. Silverstein MJ, Gierson ED, Waisman JR, et al. Predicting axillary node positivity in patients with invasive carcinoma of the breast using a combination of T category and palpability. J Am Coll Surg 1995;180:700-4.
107. Singletary SE. Management of the axilla in early-stage breast cancer. In: 34th Annual Meeting of the American Society of Clinical Oncology, Educational Book 1998;132-41.
108. Solin LJ, Fowble BL, Schultz DJ, et al. Definitive irradiation for intraductal carcinoma of the breast. Int J Radiat Oncol Biol Phys 1990;19:843-50.
109. Statman RD, Jones RC, Cabot MC, et al. Sentinel lymphadenectomy. A technique to eliminate axillary dissection in node-negative breast cancer. Proc Am Soc Clin Oncol 1996;15:A167.abstract.
110. Tabar L, Fagerberg C, Duffy SW, et al. Update of the Swedish two-country program of mammographic screening for breast cancer. Radiol Clin North Am 1992;30:187-210.
111. The Ludwig Breast Cancer Group. Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. N Engl J Med 1989;320:491-6.
112. Tinnemans JGM, Wobbes T, Holland R, et al. Treatment and survival of female patients with nonpalpable breast carcinoma. Ann Surg 1989;209:249-53.
113. Valagussa P, Bonadonna G, Veronesi U. Patterns of relapse and survival following radical mastectomy. Cancer 1978;41:1170-8.
114. Veronesi U, Sacozzi R, Del Vecchio M, et al. Comparing radical mastectomy with quadrantectomy, axillary dissection and radiotherapy in patients with small cancers of the breast. N Engl J Med 1981;305:6-11.
115. Veronesi U, Zucali R, Del Vecchio M. Conservative treatment of breast cancer with QU.A.R.T. Technique. World J Surg 1985;9:676-81.
116. Veronesi U, Banfi A, Salvadori B, et al. Breast conservation is the treatment of choice in small breast cancer. Long-term results of a randomized trial. Eur J Cancer 1990;26:668-70.
117. Veronesi U, Paganelli G, Galimberti V, et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymphnodes. Lancet 1997;349:1864-7.
118. Vilcoq JR, Calle R, Stacey P, et al. The outcome of treatment by tu-morectomy and radiotherapy of patients with operable breast cancer. Int J Radiat Oncol Biol Phys 1981;7:1327-32.
119. Von Rueden DG, Wilson RE. Intraductal carcinoma of the breast. Surg Gynecol Obstet 1984;158:105-11.
120. Walls J, Boggis CRM, Wilson M, et al. Treatment of the axilla in patients with screen-detected cancer. Br J Surg 1993;80:436-8.
121. Wazer DE, Erban JK, Robert NJ, et al. Breast conservation in elderly women for clinically negative axillary lymph nodes without axillary dissection. Cancer 1994;74:878-83.
122. Westbrook KC, Gallager HS. Intraductal carcinoma of the breast. A comparative study. Am J Surg 1975;130:667-70.
123. White RE, Vezeridia MP, Konstadoulakis M, et al. Therapeutic options and results for the management of minimally invasive carcinoma of the breast: Influence of axillary dissection for treatment of T1a and T1b lesions. J Am Coll Surg 1996;183:575-82.
124. Willner J, Kiricuta IC, Kölbl O. Beeinflußt der Primärtumor die Prognose bei lokoregionärem Rezidiv nach Mastektomie wegen Mammakarzinom? Strahlenther Onkol 1995;171:18-28.
125. Wong JH, Kopald KH, Morton KL. The impact of microinvasion on axillary node metastases and survival in patients with intraductal breast cancer. Arch Surg 1990;1298-302.